Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2000 1
2001 1
2002 2
2003 1
2005 2
2006 4
2007 1
2008 2
2009 1
2010 3
2011 3
2012 5
2013 10
2014 6
2015 7
2016 9
2017 9
2018 16
2019 14
2020 15
2021 7
2022 10
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24161323

116 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) for risk assessment in patients with established coronary artery disease.
O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS. O'Donoghue ML, et al. J Am Coll Cardiol. 2014 Feb 18;63(6):520-7. doi: 10.1016/j.jacc.2013.09.042. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161323 Free PMC article.
Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
Matsushita K, Hibi K, Komura N, Kimura Y, Matsuzawa Y, Konishi M, Maejima N, Iwahashi N, Kosuge M, Ebina T, Tamura K, Kimura K. Matsushita K, et al. J Cardiol. 2020 Jul;76(1):66-72. doi: 10.1016/j.jjcc.2020.01.005. Epub 2020 Feb 7. J Cardiol. 2020. PMID: 32037254 Free article. Clinical Trial.
Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
Suwa S, Ogita M, Miyauchi K, Sonoda T, Konishi H, Tsuboi S, Wada H, Naito R, Dohi T, Kasai T, Okazaki S, Isoda K, Daida H. Suwa S, et al. J Atheroscler Thromb. 2017 Nov 1;24(11):1125-1131. doi: 10.5551/jat.38794. Epub 2017 Mar 17. J Atheroscler Thromb. 2017. PMID: 28321012 Free PMC article. Clinical Trial.
The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nicholls SJ. Puri R, et al. Eur J Prev Cardiol. 2016 Mar;23(5):474-85. doi: 10.1177/2047487315572920. Epub 2015 Feb 17. Eur J Prev Cardiol. 2016. PMID: 25691546
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators. Mohler ER 3rd, et al. J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079. J Am Coll Cardiol. 2008. PMID: 18436114 Free article. Clinical Trial.
116 results